Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | AXL |
| Variant | act mut |
| Impact List | unknown |
| Protein Effect | gain of function |
| Gene Variant Descriptions | AXL act mut indicates that this variant results in a gain of function in the Axl protein. However, the specific amino acid change has not been identified. |
| Associated Drug Resistance | |
| Category Variants Paths |
AXL mutant AXL act mut |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04631744 | Phase II | Cabozantinib | Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Terminated | USA | 0 |
| NCT02867592 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Active, not recruiting | USA | 0 |